PTO/SB/25(10-00)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE and to a collection of information unless it displays a valid OMB control number.

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERC U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERC U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

TERMINAL DISCLAIMER TO OBVIATE A PROVISIONAL DOUBLE PATENTING	Docket Number (Optional)
REJECTION OVER A PENDING SECOND APPLICATION	SCHERING 3.0-122 CIP
In re Application of: Anil Saksena	
Application No.: 10/052,386	
Filed: January 18, 2002	
For: NOVEL PEPTIDES AS NS3-SERINE PROTEASE INHIBITORS OF HEPATITIS C VIRUS	
The owners*, Dendreon Corporation and Schering Corporation , of 100 Percent interest in the instant application hereby disclaim, except as provided below, the terminal part of the statutory term of any patent granted on the instant application, which would extend beyond the expiration date of the full statutory term defined in 35 U.S.C. 154 to 156 and 173 as shortened by any terminal disclaimer filed prior to the grant of any patent granted on pending second Application Number 09/908,955	
filed on July 19, 2001 of any patent on the pending second application. The owners hereby agree that any patent so granted on the instant application shall be enforceable only for and during such period that it and any patent granted on the second application are commonly owned. This agreement runs with any patent granted on the instant application and is binding upon the grantee, its successors or assigns. In making the above disclaimer, the owners do not disclaim the terminal part of any patent granted on the instant application that would extend to the expiration date of the full statutory term as defined in 35 U.S.C. 154 to 156 and 173 of any patent granted on the second application, as shortened by any terminal disclaimer filed prior to the patent grant, in the event that any such granted patent: expires for failure to pay a maintenance fee, is held unenforceable, is found invalid by a court of competent jurisdiction, is statutorily disclaimed in whole or terminally disclaimed under 37 CFR 1.321, has all claims canceled by a reexamination certificate, is reissued, or is in any manner terminated prior to the expiration of its full statutory term as shortened by any terminal disclaimer filed prior to its grant.	
Check either box 1 or 2 below, if appropriate.	
For submissions on behalf of an organization (e.g., corporation, partnership, university, government agency, etc.), the undersigned is empowered to act on behalf of the organization.	
I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.	
2. X The undersigned is an attorney or agent of record. Signature 3/31/05 Date	
Harvey L. Cohen Typed or printed name	
The Commissioner is hereby authorized to charge the disclaimer fee under 37 CFR 1.20(d) to Deposit Account No12-1095	
*Statement under 37 CFR 3.73(b) is required if terminal disclaimer is signed by the assignee (owner). Form PTO/SB/96 may be used for making this statement. See MPEP § 324.	
WILLIA1 00000001 121095 10052386	
I hereby castify that this correspondence is being facsimile transmitted to the Patient and Trademark Office, facsimile no. (57.1) 273-0956; on the date shown below. Dated: March 31, 2005 Signature (Harvey L. Cohen)	
Delice. Indian VI, 2000	

554851

04/01/2005 01 FC:1814

PTO/SB/97 (09-04)
Approved for use through 07/31/2006. OMB 0651-0031
U. S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Application No. (if known): 10/052,386

Attorney Docket No.: SCHERING 3.0-122 CIP

Certificate of Transmission under 37 CFR 1.8

I hereby certify that this correspondence is being facsimile transmitted to the United States Patent and Trademark Office.

March 31, 2005 Date

Harvey L. Cohen

Typed or printed name of person signing Certificate

28,365 Registration Number, if applicable (908) 518-6425

Telephone Number

Each paper must have its own certificate of transmission, or this certificate must Note: identify each submitted paper.

Terminal Disclaimer (1 page)

Charge \$130.00 to deposit account 12-1095